title: Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
abstract: The purpose of this study was to assess the prognostic value of a large panel of cytokines in aggressive non-Hodgkin's lymphoma (NHL) and to confront it to parameters of the International Prognostic Index (IPI). It investigated the concomitant determination of interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R), interleukin-4 (IL-4), interleukin-6 (IL-6) and interleukin-10 (IL-10) on a uniform population of 116 previously untreated patients. Commercially available enzyme-linked immunoassay kits were used for cytokines measurements. Results were correlated with complete remission (CR), overall survival (OS) and failure free survival (FFS). In univariate analysis, sIL-2R and IL-6 demonstrated prognostic significance for CR (p = 0.016 and p = 0.048), OS (p = 0.0011 and p = 0.0387) and FFS (p = 0.0001 and p = 0.0363), but multi-variate analysis failed to demonstrate an independent prognostic significance. In the intermediate group risk defined by IPI, patients presenting high level of sIL-2R or IL-6 demonstrated lower CR rate and survival than those with low level. In conclusion, sIL-2R and IL-6 serum levels are elevated in high grade NHL and are correlated to CR, OS and FFS, but this study did not support their independent prognostic value. However, sIL-2R and IL-6 measurements may improve risk assignment by IPI and allow a better prognostic evaluation of patients with intermediate prognosis NHL.
authors.affiliation: Department of Medical Oncology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, France. elizabetn.fabre-guillevin@egp.ap-hop-paris.fr
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fabre-Guillevin
authors.forename: Reza
authors.initials: R
authors.lastname: Tabrizi
authors.forename: Valérie
authors.initials: V
authors.lastname: Coulon
authors.forename: Alain
authors.initials: A
authors.lastname: Monnereau
authors.forename: Houchingue
authors.initials: H
authors.lastname: Eghbali
authors.forename: Isabelle
authors.initials: I
authors.lastname: Soubeyran
authors.forename: Pierre
authors.initials: P
authors.lastname: Soubeyran
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000096:biosynthesis*; D015847:Interleukin-4 / Q000096:biosynthesis*; D015850:Interleukin-6 / Q000096:biosynthesis*; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis*; D016896:Treatment Outcome
chemical_list: D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D016753:Interleukin-10; D015847:Interleukin-4